Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Dusseldorf - Delayed Quote EUR

Jazz Pharmaceuticals PLC (J7Z.DU)

Compare

140.00

+7.00

+(5.26%)

At close: February 27 at 4:00:10 PM GMT+1

Despite the downward trend in earnings at Jazz Pharmaceuticals (NASDAQ:JAZZ) the stock advances 3.2%, bringing five-year gains to 21%

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore...

Simply Wall St. yesterday

JAZZ
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2024 and provided guidance for 2025.

PR Newswire 2 days ago

JAZZ
Jazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in TD Cowen's 45th Annual Health Care Conference. Company management will participate in a fireside chat on Wednesday, March 5, 2025, at 7:30 a.m. PT / 10:30 a.m. ET / 3:30 p.m. GMT.

PR Newswire 7 days ago

JAZZ
Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 full year and fourth quarter financial results on Tuesday, February 25, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss 2024 full year and fourth quarter financial results and provide a business and financial update.

PR Newswire 16 days ago

JAZZ
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 43rd Annual J.P. Morgan Healthcare Conference. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business update on Tuesday, January 14, 2025, at 9:45 a.m. PST / 5:45 p.m. GMT.

PR Newswire 2 months ago

JAZZ
Jazz Pharmaceuticals Announces CEO Succession Plan

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Bruce Cozadd, Co-Founder, Chairperson and Chief Executive Officer (CEO), has informed the Board of Directors of his intent to retire from his role as CEO upon appointment of the Company's next leader, expected by the end of 2025. The Board will commence a formal search process to identify a new CEO, which is anticipated to conclude within 12 months. Mr. Cozadd will retire as CEO once a successor has been appointed and will continue ser

PR Newswire 2 months ago

JAZZ
Is Now The Time To Put Jazz Pharmaceuticals (NASDAQ:JAZZ) On Your Watchlist?

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Simply Wall St. 2 months ago

JAZZ
Jazz upgraded to Overweight at Morgan Stanley after Ziihera launch

Morgan Stanley upgraded Jazz Pharmaceuticals (JAZZ) to Overweight from Equal Weight with a price target of $175, up from $140, after the company hosted an investor call on Ziihera following the recent approval. Ziihera is now available to prescribers in the U.S. at a wholesale acquisition cost price of about $35,500 for a 28-day cycle, the analyst noted. With the launch of Ziihera in biliary tract cancer and Phase 3 data in gastroesophageal adenocarcinoma due in Q2 of 2025, the firm believes the

TipRanks 2 months ago

JAZZ
Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced nine company-sponsored Epidiolex® (cannabidiol) posters are being presented at the American Epilepsy Society (AES) 2024 Annual Meeting, being held December 6-10 in Los Angeles, California.

PR Newswire 2 months ago

JAZZ
Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that zanidatamab-hrii (Ziihera®) 50 mg/mL for injection for intravenous use is recommended by the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a category 2A treatment option for Biliary Tract Cancers (BTC).

PR Newswire 2 months ago

JAZZ
Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will host a webcast on Wednesday, December 11, 2024, at 4:30 p.m. ET / 9:30 p.m. GMT to provide an overview of clinical data, patient need and commercialization strategy for Ziihera® (zanidatamab-hrii), the first chemotherapy-free dual HER2-targeted bispecific antibody indicated for biliary tract cancer (BTC). Ziihera was approved under accelerated approval by the U.S. Food and Drug Administration (FDA) on November 20, 2024, for the

PR Newswire 2 months ago

JAZZ
Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present two abstracts at the 2024 San Antonio Breast Cancer Symposium (SABCS) from December 10-13 and 13 abstracts at the 66th Annual American Society of Hematology (ASH) Annual Meeting from December 7-10.

PR Newswire 2 months ago

JAZZ
Jazz Pharmaceuticals price target lowered to $163 from $166 at Piper Sandler

Piper Sandler lowered the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $163 from $166 and keeps an Overweight rating on the shares. The firm notes Jazz shares are down about 30% since the closing of the GW acquisition in May 2021, even with Epidiolex-associated diversification and the success of Xywav. Though Piper is bullish on the transformative potential of the OX2R agonists in sleep/wake, it still envisions a sizable role for oxybate products, particularly in narcolepsy type 2 and i

TipRanks 3 months ago

JAZZ
Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.1 Ziihera was approved under accelerated approval based on a 52% objective response rate (ORR) and a median duration of response (DOR) of 1

PR Newswire 3 months ago

JAZZ
Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2024 Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, December 3, 2024, at 7:15 a.m. PT / 10:15 a.m. ET / 3:15 p.m. GMT.

PR Newswire 3 months ago

JAZZ
Jazz Pharmaceuticals' (NASDAQ:JAZZ) Performance Is Even Better Than Its Earnings Suggest

When companies post strong earnings, the stock generally performs well, just like Jazz Pharmaceuticals plc's...

Simply Wall St. 3 months ago

JAZZ
Jazz Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations

Jazz Pharmaceuticals ( NASDAQ:JAZZ ) Third Quarter 2024 Results Key Financial Results Revenue: US$1.05b (up 8.5% from...

Simply Wall St. 3 months ago

JAZZ
Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2024 and updated guidance for 2024.

PR Newswire 3 months ago

JAZZ
Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eight abstracts presenting data from across its sleep portfolio were featured at the 37th annual Psych Congress, held in Boston from October 29 through November 2, 2024. The data includes the top-line results of the Phase 4 DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) trial, evaluating the effectiveness of low-sodium oxybate on key sleep outcomes in adults with narcolepsy or idiopathic hypersomnia

PR Newswire 3 months ago

JAZZ
With A 10% Return On Equity, Is Jazz Pharmaceuticals plc (NASDAQ:JAZZ) A Quality Stock?

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

Simply Wall St. 3 months ago

JAZZ

Performance Overview

Return	J7Z.DU	S&P 500
YTD	+20.17%	-0.34%
1-Year	+15.61%	+15.43%
3-Year	+13.64%	+33.68%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Jazz Pharmaceuticals PLC (J7Z.DU)

Despite the downward trend in earnings at Jazz Pharmaceuticals (NASDAQ:JAZZ) the stock advances 3.2%, bringing five-year gains to 21%

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance

Jazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference

Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025

Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jazz Pharmaceuticals Announces CEO Succession Plan

Is Now The Time To Put Jazz Pharmaceuticals (NASDAQ:JAZZ) On Your Watchlist?

Jazz upgraded to Overweight at Morgan Stanley after Ziihera launch

Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting

Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)

Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024

Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting

Jazz Pharmaceuticals price target lowered to $163 from $166 at Piper Sandler

Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference

Jazz Pharmaceuticals' (NASDAQ:JAZZ) Performance Is Even Better Than Its Earnings Suggest

Jazz Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations

Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results

Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia

With A 10% Return On Equity, Is Jazz Pharmaceuticals plc (NASDAQ:JAZZ) A Quality Stock?

Performance Overview